Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SAN DIEGO, June 01, 2017 -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that the Company will take part in multiple investor conferences in June.
Hamza Suria, president and chief executive officer, will present a corporate overview of AnaptysBio at the Jefferies Global Healthcare Conference on Thursday, June 8, 2017 at 2:00 p.m. ET in New York City. In addition, Mr. Suria will participate in a company panel discussion titled, “Inflammation and Immunology: Restoring a Fine Balance,” at the JMP Securities Healthcare Conference on Tuesday, June 20, 2017 at 4:30 p.m. ET in New York City.
A live audio webcast of the Jefferies Global Healthcare Conference presentation will be available through the investor section of the AnaptysBio website. An archived replay will be available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene. For further information, visit www.anaptysbio.com.
Contact: Monique Allaire THRUST Investor Relations 617.895.9511 [email protected]
